Who is sponsoring NCT04954040?

NCT04954040 is sponsored by Maimónides Biomedical Research Institute of Córdoba.

What drugs are being tested in NCT04954040?

Interventions in NCT04954040: Hydroxychloroquine Pill + Azithromycin Pill, SOC.

What condition does NCT04954040 study?

NCT04954040 studies Acute Respiratory Distress Syndrome, Covid19.

Is NCT04954040 still recruiting?

NCT04954040 is currently status unknown. Last updated 7 July 2021.

Last reviewed 2021-07-07 · How we verify

NCT04954040: AMBUCOV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19

Status unknown Phase 2 Last updated 7 July 2021

What this trial tests

Phase 2 trial testing Hydroxychloroquine Pill + Azithromycin Pill in Acute Respiratory Distress Syndrome in 132 participants. Status unknown.

Timeline

10 February 2021

Primary endpoint
1 October 2021

1 December 2021

Quick facts

Lead sponsor	Maimónides Biomedical Research Institute of Córdoba
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	132
Start date	10 February 2021
Primary completion	1 October 2021
Estimated completion	1 December 2021
Sites	1 location across Spain

Drugs / interventions tested

Hydroxychloroquine Pill + Azithromycin Pill — full drug profile →
SOC

Conditions studied

Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Covid19 — all drugs for Covid19 →

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Who can join

Adults 18 to 90, any sex, with Acute Respiratory Distress Syndrome or Covid19. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hospitalization
Time frame: From randomization until patient's hospitalization happens, assessed up to 28 days.
ICU admission
Time frame: From date of randomization until ICU admission as a result of COVID19, assessed up to 28 days.
Death
Time frame: From randomization until death by any cause related to COVID19, assessed up to 28 days.

Sponsor's own description

Multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
NCT07289711 — Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter C · recruiting
NCT07326215 — A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ · NA · recruiting
NCT06919484 — The Physiological Effect of RCexp on Ventilation/Perfusion Distribution · recruiting
NCT07126964 — Extended Prone Positioning for Intubated ARDS · NA · recruiting

Other Maimónides Biomedical Research Institute of Córdoba trials

Trials by the same sponsor.

NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
NCT07479303 — Vitamin D Status in Young Medical Residents · completed
NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04954040 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
Last refreshed: 7 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing